{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:15:46Z","timestamp":1764828946921,"version":"3.41.2"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 109-2320-B-006-047-MY3)"],"award-info":[{"award-number":["MOST 109-2320-B-006-047-MY3)"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>We assessed the effects of sodium glucose cotransporter-2 inhibitors (SGLT2is) versus dipeptidyl peptidase-4 inhibitors (DPP4is) in a large real-world Asian cohort with type 2 diabetes (T2D) and performed a systematic review with integrating the present study findings to provide up-to-date evidence from the Asian perspective.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>New users of SGLT2is or DPP4is were identified from the Taiwan\u2019s National Health Insurance Research Database and followed until 2018. Primary outcomes were hospitalization for heart failure (HHF) and three-point major adverse cardiovascular event (3P-MACE; namely, myocardial infarction [MI], stroke, or cardiovascular death). Other outcomes included all-cause death, chronic kidney disease (CKD), amputation, and hospitalized hypoglycemia. Subdistribution hazard models were employed to assess treatment-associated clinical outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 21,329 SGLT2i and DPP4i propensity-score-matched pairs were analyzed. SGLT2is versus DPP4is showed lower risks of HHF (hazard ratio [95% CI]: 0.52 [0.45\u20130.59]), 3P-MACE (0.62 [0.55\u20130.70]), MI (0.63 [0.50\u20130.79]), stroke (0.60 [0.51\u20130.70]), all-cause death (0.57 [0.49\u20130.67]), CKD (0.46 [0.43\u20130.50]), amputation (0.64 [0.42\u20130.98]), and hospitalized hypoglycemia (0.54 [0.45\u20130.64]). Our results were consistent with findings from a systematic review.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Among Asian patients with T2D, SGLT2is versus DPP4is showed benefits for several clinical outcomes. More research is warranted to explore the heterogeneous treatment effects of SGLT2is and DPP4is by race\/ethnicity.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.836365","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T09:28:28Z","timestamp":1646645308000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Cardiovascular Benefits With Favorable Renal, Amputation and Hypoglycemic Outcomes of SGLT-2 Inhibitors in Type 2 Diabetes From the Asian Perspective: A Population-Based Cohort Study and Systematic Review"],"prefix":"10.3389","volume":"13","author":[{"given":"Chun-Ting","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Yang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Chi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huang-Tz","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihchen","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S009","article-title":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes\u20142021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.6139","article-title":"Association of Race\/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US","volume":"4","author":"Eberly","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13687","article-title":"Time Trends in Prescribing of Type 2 Diabetes Drugs, Glycaemic Response and Risk Factors: A Retrospective Analysis of Primary Care Data, 2010-2017","volume":"21","author":"Dennis","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-019-02751-9","article-title":"National Trends in Metformin-Based Combination Therapy of Oral Hypoglycaemic Agents for Type 2 Diabetes Mellitus","volume":"75","author":"Kim","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177646","article-title":"Comparative Effectiveness of Oral Antidiabetic Drugs in Preventing Cardiovascular Mortality and Morbidity: A Network Meta-Analysis","volume":"12","author":"Lee","year":"2017","journal-title":"PloS One"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3024","article-title":"Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis","volume":"319","author":"Zheng","year":"2018","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","first-page":"k119","DOI":"10.1136\/bmj.k119","article-title":"Cardiovascular Outcomes Associated With Canagliflozin Versus Other non-Gliflozin Antidiabetic Drugs: Population Based Cohort Study","volume":"360","author":"Patorno","year":"2018","journal-title":"BMJ"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13077","article-title":"Dapagliflozin Is Associated With Lower Risk of Cardiovascular Events and All-Cause Mortality in People With Type 2 Diabetes (CVD-REAL Nordic) When Compared With Dipeptidyl Peptidase-4 Inhibitor Therapy: A Multinational Observational Study","volume":"20","author":"Persson","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"l4772","DOI":"10.1136\/bmj.l4772","article-title":"Use of Sodium Glucose Cotransporter 2 Inhibitors and Risk of Major Cardiovascular Events and Heart Failure: Scandinavian Register Based Cohort Study","volume":"366","author":"Pasternak","year":"2019","journal-title":"BMJ"},{"key":"B10","doi-asserted-by":"publisher","first-page":"m3342","DOI":"10.1136\/bmj.m3342","article-title":"Sodium Glucose Cotransporter 2 Inhibitors and Risk of Major Adverse Cardiovascular Events: Multi-Database Retrospective Cohort Study","volume":"370","author":"Filion","year":"2020","journal-title":"BMJ"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30130-3","article-title":"CVD-REAL 2 Investigators and Study Group. Risk of Cardiovascular Events and Death Associated With Initiation of SGLT2 Inhibitors Compared With DPP-4 Inhibitors: An Analysis From the CVD-REAL 2 Multinational Cohort Study","volume":"8","author":"Kohsaka","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/nyas.12098","article-title":"Type 2 Diabetes in East Asians: Similarities and Differences With Populations in Europe and the United States","volume":"1281","author":"Ma","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4557-7","article-title":"Epidemiology of Diabetes and Diabetic Complications in China","volume":"61","author":"Ma","year":"2018","journal-title":"Diabetologia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e00183","DOI":"10.1002\/edm2.183","article-title":"Cardiovascular and Renal Effectiveness of Empagliflozin in Routine Care in East Asia: Results From the EMPRISE East Asia Study","volume":"4","author":"Seino","year":"2021","journal-title":"Endocrinol Diabetes Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/dom.14189","article-title":"Lower Cardiorenal Risk With Sodium-Glucose Cotransporter-2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes Without Cardiovascular and Renal Diseases: A Large Multinational Observational Study","volume":"23","author":"Birkeland","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/jdi.13321","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors Compared With Other Glucose-Lowering Drugs in Japan: Subanalyses of the CVD-REAL 2 Study","volume":"12","author":"Kohsaka","year":"2021","journal-title":"J Diabetes Investig"},{"key":"B17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/dom.14119","article-title":"Lower Heart Failure and Chronic Kidney Disease Risks Associated With Sodium-Glucose Cotransporter-2 Inhibitor Use in Japanese Type 2 Diabetes Patients Without Established Cardiovascular and Renal Diseases","volume":"23","author":"Komuro","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12933-020-01162-w","article-title":"The Risk of New-Onset Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus Treated With Sodium Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors","volume":"19","author":"Ling","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12933-020-01060-1","article-title":"Comparison of Heart Failure Risk and Medical Costs Between Patients With Type 2 Diabetes Mellitus Treated With Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors: A Nationwide Population-Based Cohort Study","volume":"19","author":"Seong","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12933-018-0737-5","article-title":"Association Between Sodium Glucose Co-Transporter 2 Inhibitors and a Reduced Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Real-World Nationwide Population-Based Cohort Study","volume":"17","author":"Kim","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14261","article-title":"Effectiveness and Safety of Sodium-Glucose Co-Transporter-2 Inhibitors Compared With Dipeptidyl Peptidase-4 Inhibitors in Older Adults With Type 2 Diabetes: A Nationwide Population-Based Study","volume":"23","author":"Han","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B22","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12933-020-01118-0","article-title":"Major Adverse Cardiovascular and Limb Events in Patients With Diabetes and Concomitant Peripheral Artery Disease Treated With Sodium Glucose Cotransporter 2 Inhibitor Versus Dipeptidyl Peptidase-4 Inhibitor","volume":"19","author":"Lee","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S196293","article-title":"Taiwan\u2019s National Health Insurance Research Database: Past and Future","volume":"11","author":"Hsieh","year":"2019","journal-title":"Clin Epidemiol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s40471-015-0053-5","article-title":"The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary Application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2262","article-title":"Association of Renal and Cardiovascular Safety With DPP-4 Inhibitors vs. Sulfonylureas in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease","volume":"110","author":"Yang","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"B26","unstructured":"ParsonsL\n          Reducing Bias in a Propensity Score Matched-Pai Sample Using Greedy Matching Techniques"},{"key":"B27","unstructured":"YangD\n            DaltonJE\n          A Unified Approach to Measuring the Effect Size Between Two Groups Using SAS. SAS Global Forum 2012: Statistics and Data Analysis, Paper 335-2012"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the Analysis of Survival Data in the Presence of Competing Risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"B29","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Healthcare Interventions: Explanation and Elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13297","article-title":"Sodium-Glucose Co-Transporter-2 Inhibitors and the Risk of Ketoacidosis in Patients With Type 2 Diabetes Mellitus: A Nationwide Population-Based Cohort Study","volume":"20","author":"Kim","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B31","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12933-020-01105-5","article-title":"SGLT2 Inhibitors and Atrial Fibrillation in Type 2 Diabetes: A Systematic Review With Meta-Analysis of 16 Randomized Controlled Trials","volume":"19","author":"Li","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-2940-y","article-title":"UKPDS Outcomes Model 2: A New Version of a Model to Simulate Lifetime Health Outcomes of Patients With Type 2 Diabetes Mellitus Using Data From the 30 Year United Kingdom Prospective Diabetes Study: UKPDS 82","volume":"56","author":"Hayes","year":"2013","journal-title":"Diabetologia"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2888","article-title":"The Global Burden of Atrial Fibrillation and Stroke: A Systematic Review of the Epidemiology of Atrial Fibrillation in Regions Outside North America and Europe","volume":"142","author":"Lip","year":"2012","journal-title":"Chest"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.07.026","article-title":"Age Threshold for Increased Stroke Risk Among Patients With Atrial Fibrillation: A Nationwide Cohort Study From Taiwan","volume":"66","author":"Chao","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.117.018773","article-title":"Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation","volume":"48","author":"Cha","year":"2017","journal-title":"Stroke"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.115.009947","article-title":"Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis","volume":"46","author":"Wang","year":"2015","journal-title":"Stroke"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1177\/1747493020909545","article-title":"Global Stroke Statistics 2019","volume":"15","author":"Kim","year":"2020","journal-title":"Int J Stroke"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.018820","article-title":"Global Variation in the Relative Burden of Stroke and Ischemic Heart Disease","volume":"124","author":"Kim","year":"2011","journal-title":"Circulation"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1186","article-title":"Use of Sodium-Glucose Co-Transporter 2 Inhibitors and Risk of Serious Renal Events: Scandinavian Cohort Study","volume":"369","author":"Pasternak","year":"2020","journal-title":"BMJ"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1890","article-title":"Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases","volume":"43","author":"Xie","year":"2020","journal-title":"Diabetes Care"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13459","article-title":"Risk of Amputations Associated With SGLT2 Inhibitors Compared to DPP-4 Inhibitors: A Propensity-Matched Cohort Study","volume":"20","author":"Adimadhyam","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.3034","article-title":"Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes","volume":"178","author":"Chang","year":"2018","journal-title":"JAMA Intern Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0267","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study","volume":"43","author":"Yu","year":"2020","journal-title":"Diabetes Care"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2168.2000.01344.x","article-title":"Epidemiology of Lower Extremity Amputation in Centres in Europe, North America and East Asia","volume":"87","author":"Unwin","year":"2000","journal-title":"Br J Surg"},{"key":"B45","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2337\/diacare.26.2.495","article-title":"Effects of Ethnicity and Nephropathy on Lower-Extremity Amputation Risk Among Diabetic Veterans","volume":"26","author":"Young","year":"2003","journal-title":"Diabetes Care"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.8.1869","article-title":"Foot Ulcer Risk Is Lower in South-Asian and African-Caribbean Compared With European Diabetic Patients in the U.K.: The North-West Diabetes Foot Care Study","volume":"28","author":"Abbott","year":"2005","journal-title":"Diabetes Care"},{"key":"B47","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1046\/j.1464-5491.2002.00583.x","article-title":"Risk of Diabetes-Related Amputation in South Asians vs. Europeans in the UK","volume":"19","author":"Chaturvedi","year":"2002","journal-title":"Diabetes Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.836365\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T09:28:33Z","timestamp":1646645313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.836365\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,7]]},"references-count":47,"alternative-id":["10.3389\/fendo.2022.836365"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.836365","relation":{},"ISSN":["1664-2392"],"issn-type":[{"type":"electronic","value":"1664-2392"}],"subject":[],"published":{"date-parts":[[2022,3,7]]},"article-number":"836365"}}